Inositol phosphates (IPs), such as 1,4,5-inositol-trisphosphate (IP 3 ), comprise a ubiquitous intracellular signaling cascade initiated in response to G protein-coupled receptor-mediated activation of phospholipase C. Classical methods for measuring intracellular accumulation of these molecules include time-consuming high-performance liquid chromatography (HPLC) separation or large-volume, gravity-fed anion-exchange column chromatography. More recent approaches, such as radioreceptor and AlphaScreen™ assays, offer higher throughput. However, these techniques rely on measurement of IP 3 itself, rather than its accumulation with other downstream IPs, and often suffer from poor signal-to-noise ratios due to the transient nature of IP 3 . The authors have developed a miniaturized, anion-exchange chromatography method for measuring inositol phosphate accumulation in cells that takes advantage of signal amplification achieved through measuring IP 3 and downstream IPs. This assay uses centrifugation of 96-well-formatted anion-exchange mini-columns for the isolation of radiolabeled inositol phosphates from cell extracts, followed by low-background dry-scintillation counting. This improved assay method measures receptor-mediated IP accumulation with signal-to-noise and pharmacological values comparable to the classical large-volume, column-based methods. Assay validation data for recombinant muscarinic receptor 1, galanin receptor 2, and rat astrocyte metabotropic glutamate receptor 5 are presented. This miniaturized protocol reduces reagent usage and assay time as compared to large-column methods and is compatible with standard 96-well scintillation counters. (Journal of Biomolecular Screening 2004:343-353) 348 www.sbsonline.org Journal of Biomolecular Screening 9(4); 2004 Benjamin et al. FIG. 2. Inositol phosphate (IP) accumulation using the large-volume, gravity-fed column reference assay. (A) IP accumulation in response to carbachol, as well as a block by antagonists pirenzipine and telenzepine, is demonstrated in CHO-M1 cells. Data are depicted from 1 experiment, representative of 4 with similar results. (B) IP accumulation response to hGalanin is demonstrated in hGalR 2 -HEK cells. Raw data are depicted from 1 experiment, representative of 3 with similar results. (C) IP accumulation response to quisqualate, as well as a block by antagonists MPEP and Sibia 1893, is demonstrated in primary rat astrocytes. Data are depicted from 1 experiment, representative of 5 with similar results. The data points in each panel are the mean ± SEM of 3 to 4 wells. 350 www.sbsonline.org Journal of Biomolecular Screening 9(4); 2004 Benjamin et al. FIG. 5. Validation of the 96-well-formatted mini-column assay for hGalR 2 -HEK cells. (A) The inositol phosphate (IP) accumulation response to hGalanin and M35 GalR2 peptides is demonstrated in hGalR 2 -HEK cells. Data are depicted from 1 experiment, representative of 3 with similar results. Each data point is the mean ± SEM of 4 to 8 wells. (B) Concentration-dependent stimulation of IP accumulation was measured for hGalanin and M35. Data points represent the mean ± SEM of 3 independent experiments normalized to percentage of control, as described in Materials and Methods.
INTRODUCTION
T HE SIGNALING OF MANY NEUROTRANSMITTERS AND HORMONES is critically dependent on G protein-coupled receptor (GPCR) activated cascades that involve intracellular effector enzyme activation and consequent changes in the levels of intracellular second-messenger molecules. 1 Inositol-1,4,5trisphosphate (IP 3 ), generated in response to phospholipase C (PLC) activation, is the predominant intracellular second messenger that links Gq-coupled GPCR activation to changes in intracellular calcium concentration. 2 This molecule, a product of inositol phosphate (IP) metabolism, has been implicated in numer-ous fundamental physiological processes, including muscle contraction, plasma membrane depolarization, platelet aggregation, and learning and memory. 3, 4 A variety of methods have been applied to investigate receptoractivated IP metabolism and associated concentration changes of specific intermediates within this metabolic pathway. Informationrich methods, such as gas chromatography/mass spectrometry (GC/MS), exquisitely resolve levels of individual IP molecular species, including inositol monophosphate (IP 1 ), inositol disphosphate (IP 2 ), IP 3 , and inositol tetrakisphosphate (IP 4 ) with high sensitivity. 5 Comprehensive high-performance liquid chromatography (HPLC) methods also have been developed to accurately analyze specific IP molecular species with high sensitivity 6 and can be combined with preradiolabeling of the samples. 7 Although highly sensitive, these analytical methods are time-consuming, laborious, and expensive, making them unsuitable for pharmacological compound profiling or screening large compound libraries.
Indirect quantification of cellular IP 3 levels also has been reported using competition binding of [ 3 H]IP 3 to its receptor. 8, 9 More recently, a homogeneous, amplified luminescent proximity assay [10] [11] [12] [13] has become available that also uses a competition bind-ing principle. IP 3 from the sample competitively disrupts the binding of a biotinylated IP 3 analog to an IP 3 binding protein tagged with glutathione-S-transferase (GST). In the absence of exogenous IP 3 , this binding event brings a streptavidin-coated donor bead into close proximity with an anti-GST acceptor bead. Upon laser excitation, the donor bead emits singlet-state oxygen molecules that react with the acceptor bead to generate light. In the presence of exogenous IP 3 , light emission is decreased due to disruption of the binding reaction that causes a loss of close coupling between the donor-acceptor bead pair. These assays are high throughput, do not require advanced analytical skills, and are amenable to miniaturization. However, they can suffer from poor signal-to-noise ratios and have critical timing issues as they specifically measure changes in the levels of IP 3 itself. IP 3 is rapidly metabolized and may be undetectable within seconds of agonist addition. Its half-life depends on GPCR expression levels and desensitization kinetics. Thus, these assays are difficult to apply to rapidly desensitizing GPCRs and to cells that express low receptor levels, a property of many primary cell cultures.
A final common, classical method for measuring receptormediated IP production 14 14 [ 3 H] IPs are resolved by anion-exchange chromatography, and metabolically incorporated radioactivity is measured using scintillation counting. This method is less precise and less sensitive than more intricate HPLC-or GC/MS-based techniques because it cannot resolve individual IP molecular species. 7 However, it does not require sophisticated equipment or extensive analytical expertise and has proven useful for compound screening and pharmacological profiling. It has been successfully applied to a number of GPCRs that signal through PLC and to a variety of cell types, including primary cell cultures. [15] [16] [17] [18] The drawback to this method currently is that it is still labor intensive and time-consuming and requires large quantities of reagents. Therefore, we have adapted the general principles of this method to a novel, miniaturized protocol with a comparatively improved throughput. Our assay uses centrifugation of 96-well-formatted anion-exchange mini-columns for the isolation of radiolabeled IPs from cell extracts, followed by lowbackground dry-scintillation counting. This improved assay method reliably measures receptor-mediated IP accumulation with signal-to-noise and pharmacological values comparable to the classical large-volume, column-based methods. This assay works in a broad range of cell types, including recombinant and primary cell systems. It is amenable to compound library screening and pharmacological profiling. Measurements are not limited to receptor-mediated increases in IP 3 specifically, but also include downstream IPs. Further recycling of these molecules back to free inositol is prevented through inhibition of inositol monophosphatase. 14 Therefore, this assay retains the advantages of signal amplification, as well as less critical timing issues characteristic of classical column chromatography techniques, yet offers the additional advantages of a miniaturized format and improved throughput.
MATERIALS AND METHODS

Materials
CHO-M1 cells were a gift from Molecular Devices (Sunnyvale, CA). [ 3 H]myo-inositol was purchased from Amersham Biosciences Corp. (Piscataway, NJ). Cell culture and molecular biology reagents were purchased from Invitrogen Corporation (Carlsbad, CA) unless otherwise noted. hGalanin and M35 peptides were purchased from American Peptide Co. (Sunnyvale, CA). Epidermal growth factor (EGF) was purchased from Upstate Biotechnology (Lake Placid, NY). Dowex AG-1x8 anion-exchange resin was purchased from BioRad (Hercules, CA). Quisqualate and 2-methyl-6-(phenylethynyl)-pyridine (MPEP) were purchased from Tocris Neuramin (Bristol, UK). All other chemicals were obtained from Sigma.
Cloning and stable hGalR 2 -HEK cell line development
First-strand cDNA was synthesized from 9-µg adult human brain total RNA (Clontech, Palo Alto, CA) in a final volume of 50 µL using Thermoscript reverse transcriptase and oligo(dT) 20 at 55°C, 1 h. Human galanin receptor type 2 (hGalR 2 ; NM_003857.2 19 ) was amplified from the first-strand cDNA (2 µL) by polymerase chain reaction 20, 21 using Amplitaq Gold (Applied Biosystems, Foster City, CA) and the following oligonucleotides: sense strand ( 5′ AGCGGTACCATGAACGTC-TCGGGCTGCCCA 3′ ) and antisense strand ( 5′ CGCGAATTCTAAGTGCTT-TCAGGCCAC ATC 3′ ). The oligonucleotides were designed to encode the restriction sites Asp718I and EcoRI, respectively, immediately outside the hGalR 2 coding region for oriented, forced cloning. The 1191bp cDNA product was digested with the restriction endonucleases Asp718I and EcoRI and inserted into the expression vector pcDNA3.1(+). Clones encoding wild-type hGalR 2 were identified by dideoxy chain termination DNA sequencing using an ABI PRISM 3700 DNA Analyzer (Applied Biosystems, Inc.).
The hGalR 2 cDNA expression construct was transfected into human embryonic kidney (HEK293) cells by the lipofectamine Plus reagent, essentially as described by the supplier. Briefly, 10 µg cDNA construct was incubated 15 min with 60 µL Plus reagent in 0.2 mL Optimem I. A 40-µL aliquot of lipofectamine in an additional 0.2-mL Optimem I then was added to the mixture, and complexes were allowed to form for 15 min. Complexes were then diluted with 0.8 mL Optimem I and layered onto a 80% confluent monolayer of HEK293 cells in a 10-cm plastic dish, and the cells were incubated at 37°C, 5% CO 2 . After a 3-h incubation, the media were replaced with normal growth media composed of Dulbecco's modified Eagle's medium (DMEM) with 4.5 g/L glucose, 2 mM L-glutamine, 10% fetal bovine serum (FBS, HyClone, Logan, UT), 100 U/mL penicillin, and 100 µg/mL streptomycin. Following an additional 20-h incubation, media were aspirated and cells treated with 3 mL 0.05% Trypsin, 0.053 mM ethylenediaminetetraacetic acid (EDTA) for 10 min and gently resuspended in 50 mL growth media containing 500 µg/mL G418 (geneticin). Cells were split in limiting dilution into multiple 96-well plates in the selective media and incubated for 3 weeks at 37°C, 5% CO 2 , 95% humidity. Whole plates containing 1 clone per well were replicated by trypsinization and cells incubated further until the majority of clones were confluent. Replicate plates were washed once with Hanks buffer and cells loaded 1 h with the Ca 2+ -sensitive dye fluo4-AM (Molecular Probes). Cells were washed again, and the binding of intracellular Ca 2+ to the dye was measured and expressed as relative fluorescence change using a fluorometric imaging plate reader (FLIPR 96 , Molecular Devices, Inc.) after incubation with 1 µM hGalanin (1-30)-NH 2 peptide. The most robust stable cell line was expanded, characterized, and used for subsequent studies.
Culturing of recombinant cell lines
hGalR 2 -HEK and CHO-M1 cells were routinely grown and subcultured in DMEM, 10% FBS, 100 U/mL penicillin, 100 µg/ mL streptomycin, and 200 µg/mL G418 growth media.
Preparation and culturing of primary rat astrocytes
Primary glial cultures were prepared from cortices of Sprague-Dawley 18-day-old embryos. The cortices were harvested and then dissociated by trituration. All animal procedures were approved by an institutional animal care and use committee (IACUC). Dissociated cells were plated onto poly-D-lysine precoated T175 flasks (Biocoat, Becton Dickinson, Franklin Lakes, NJ) in DMEM, 25 mM HEPES, and 15% fetal bovine serum (FBS, pH 7.4) and incubated at 37°C and 5% CO 2 . After 24 h, FBS supplementation was reduced to 10%. On day 6, oligodendrocyte and microglia were removed by strongly tapping the sides of the flasks. After 24 h in culture, secondary astrocyte cultures were established by subplating onto 96-well poly-Dlysine precoated plates (Biocoat, Becton Dickinson, Franklin Lakes, NJ) at a density of 65,000 cells/well in DMEM, 10% FBS. After 24 h, astrocytes were washed with serum-free medium and then cultured in DMEM, without glutamine, supplemented with 0.5% FBS, 20 mM HEPES, 10 ng/mL EGF, 1 mM sodium pyruvate, 100 U/mL penicillin, and 100 µg/mL streptomycin (pH 7.5) (referred to as astrocyte-defined media [ADM]) for 3 to 5 days at 37°C and 5% CO 2 . The procedure allows the expression of the metabotropic glutamate receptor 5 (mGluR5) by astrocytes, as reported previously. 22 
Large-volume, gravity-fed column reference assay
The steps for this assay are diagrammed in Figure 1 . The day prior to the assay, CHO-M1 or hGalR 2 -HEK were seeded onto tis-sue culture-treated 12-well plates (Corning Life Sciences, Acton, MA), or rat primary astrocytes were seeded onto poly-D-lysine precoated 12-well plates (Biocoat, Becton Dickinson, Franklin Lakes, NJ) at a density of 1 million cells/well, with a volume of 1.5 mL growth media per well or ADM for the primary astrocytes. Cells were allowed to attach for at least 7 h. That evening, media were removed and replaced with either DMEM containing no FBS or ADM at 1.5 mL per well. Then, 5 µCi of [ 3 H]myo-inositol was added to each well. Cells were incubated overnight at 37°C, 5% CO 2 and assayed the next morning. The day of the assay, media were removed and cells washed 3 times with lithium chloridecontaining assay buffer (127 mM NaCl, 5 mM KCl, 2 mM MgCl 2 , 700 µM NaH 2 PO 4 , 2 mM CaCl 2 , 5 mM NaHCO 3 , 8 mM HEPES, 10 mM glucose, 10 mM LiCl, pH 7.4). Antagonists or equal-volume dimethylsulfoxide (DMSO)-containing buffer (vehicle) were added 20 min prior to agonists or vehicle. DMSO was held constant at 1%. Compounds were diluted down to their final desired concentrations from 10-mM DMSO stocks, except for glutamate, which was dissolved as a 100-mM stock solution in water carefully adjusted to pH 7.4, and stored frozen until use. Agonist stimulation was carried out for 20 min at room temperature. IPs were analyzed by anion-exchange chromatography as described previously. 23, 24 However, important steps of this IP analysis method will be described here briefly for comparative purposes with the 96-well mini-column assay.
After agonist stimulation, the reaction was stopped with 4% perchloric acid (PCA), and plates were incubated on ice for 30 min. Cells were scraped from each well, and 1.5 mL of lysates per well was collected into tubes. An equal volume of 1:1 trioctylamine/trichlorotrifluoroethane and 1 mM EDTA was added, then vortexed and centrifuged at 20,000g for 5 min to extract the PCA. Phenol red was added to the samples at a final concentration of 1 mg/mL, followed by 10 µL Tris-HCl (pH 8.5) to achieve light-pink neutral pH. Sample preparation averaged approximately 2 h per 24 samples.
After preparation, samples were placed onto freshly prepared Dowex AG-1x8 anion-exchange resin-packed (resin/H 2 O, 1:1 v/v) 10-mL polypropylene gravity columns. Unconverted inositol was removed with 12 mL of water and discarded. IP 1 , IP 2 , and IP 3 were eluted with 4 mL of 0.8 M ammonium formate into 20-mL scintillation vials. Column preparation, elution, and wash steps averaged approximately 2 h. Then, 10 mL scintillation fluid (Ready Safe, Beckman-Coulter) was added and counted in a Beckman LS6000 scintillation counter. The total time to run this assay, including cell stimulation sample preparation and chromatography, was approximately 5 h per 24 wells, excluding read time.
96-well-formatted mini-column assay
The steps for this assay are diagrammed for direct comparison to the large-volume column assay in Figure 1 . Cells were plated into 2 to 3 T150 flasks and grown to a confluent monolayer in normal growth media or ADM for rat primary astrocytes. The evening before the assay, media were removed, and 1 to 2 flasks of cells were washed with phosphate-buffered saline (PBS, Invitrogen) and replaced with 6 µCi [ 3 H]myo-inositol/mL DMEM (containing no FBS) or fresh ADM. One parallel flask was replaced with media containing no radioactivity for cell counting the next day. Flasks were incubated overnight at 37°C, 5% CO 2 for approximately 16 to 20 h. The morning of the assay, cells in the parallel flask were detached with 5 mM EDTA in PBS (pH 7.4), washed twice in PBS by resuspension and centrifugation at 150g, and counted to determine the approximate number of cells per flask. Afterward, cells in the labeled flasks were detached, washed twice with PBS, and resuspended to the desired number of cells/mL in a lithium chloride-containing assay buffer.
To each well of a 96-well polypropylene plate (Corning Life Sciences, Acton, MA), 100-µL cells were added. Then, 10 µL antagonist or buffer control was added to each well and mixed 20 min prior to the 10-µL addition of agonists. Agonist stimulation was carried out at room temperature for 20 min unless otherwise indicated. The reactions were stopped by addition and mixing of PCA (4% final), followed by a 30-min incubation of the plate at 4°C. Samples were centrifuged at 3800g for 20 min to pellet membranes. Then, 100-µL supernatants were transferred to a fresh 96well polypropylene plate containing 3 µL 25% NaOH w/w to neutralize pH. Samples were then transferred to a 96-well-formatted block of Captiva mini-columns (Ansys Technologies, Inc., Lake Forest, CA). The columns had been freshly packed with Dowex AG-1x8 anion-exchange resin by addition of 400 µL (unless otherwise indicated) of 1:1 resin to dH 2 O, followed by a brief centrifugation (2 min) into a Captiva collection plate to remove the dH 2 O just prior to sample addition. Unconverted inositol was removed by addition and centrifugation (2 min) of 300 µL dH 2 O twice and discarded. IP 1 , IP 2 , and IP 3 were eluted by addition of 300 µL 0.8 M ammonium formate and centrifugation (2 min) into a fresh 500-µL assay block. Eluant was then transferred to a Deepwell LumaPlate-96 (2 min) (PerkinElmer, Boston, MA), a solid scintillator-coated microplate that eliminates the need for a liquid scintillation cocktail and that exhibits exceptionally lowbackground luminescence. Eluant was evaporated at 48°C in an oven overnight. Counts per minute (cpm) were then read from dry plates on a TopCount NXT (PerkinElmer). The total time to run this assay, including cell dilution and stimulation, sample preparation, and chromatography, is ≤ 2.5 h per 96 wells, excluding the overnight evaporation step and read time.
hGalanin calcium measurements in hGalR 2 -HEK cells
Cells were seeded into poly-d-lysine precoated black-wall, clear-bottom 96-well plates (Biocoat, Beckton Dickinson) at 75,000 cells/well in 100 µL growth media 24 h prior to the assay. On the day of assay, cells were washed once with 100 µL assay buffer consisting of 1× HEPES-buffered saline solution (Invitrogen), 20 mM HEPES, and 1.6 mM CaCl 2 , pH 7.4. Cells then were loaded for 1 h at 37°C, 5% CO 2 with 100 µL/well 2 µM fluo-4 AM dissolved in assay buffer. After loading, cells were washed twice with assay buffer, replaced with a 50-µL assay buffer, and then placed onto the stage of a FLIPR. The FLIPR protocol was designed to monitor baseline fluorescence for 15 sec, then add 50 µL of 2× agonist dilution to each corresponding well of the cell plate and monitor fluorescence response for an additional 120 sec.
Data analysis
Some experiments were expressed as percentage of control. The percentage of control data that are shown is the average of 3 independent experiments, each of which contained triplicate determinations for each point on the curve, normalized to the maximum average cpm in the presence of the highest concentration of agonist and to the minimum average cpm in the presence of buffer. Normalization calculations were conducted using GraphPad Prism version 3.02 software (San Diego, CA). Theoretical curves were generated using nonlinear regression curve-fitting analysis in GraphPad Prism version 3.02. The following p-values-*p < 0.05, **p < 0.01, and ***p < 0.001-were determined by 1-way analysis of variance (ANOVA), followed by Bonferroni's multiplecomparisons test for comparisons of 3 or more groups using GraphPad Prism version 3.02 software. P-values were determined by an unpaired t-test for comparisons of 2 groups using GraphPad Prism version 3.02 software. Whenever indicated, K b values were calculated from experimentally determined IC 50 values using the general Cheng-Prusoff relationship 25, 26 as follows: K b = IC 50 /(2 + ([agonist]/EC 50 ) n ) 1/n -1, where n = slope of the agonist concentration response curve.
RESULTS
M1-, hGalR 2 -, and mGluR5-mediated IP accumulation in the large-volume, gravity-fed column reference assay
IP accumulation was briefly evaluated in the large-volume, gravity-fed, column-based assay to establish reference signal-tonoise ratios for 3 Gq-coupled GPCR targets. Agonists carbachol, galanin, and quisqualate induced significant IP accumulation in CHO cells stably transfected with human muscarinic-1 (M1) receptor, in HEK-293 cells stably transfected with human galanin receptor 2 (hGalR 2 ) receptor, and in rat primary astrocytes endogenously expressing metabotropic glutamate receptor 5 (mGluR5), respectively ( Fig. 2A-C) . The average signal-to-noise ratio (mean ± SEM) for each of these receptors was as follows: for CHO-M1, 10 µM carbachol versus buffer was 5.7-± 1.3-fold (n = 6); for hGalR 2 -HEK, 100 nM galanin versus buffer was 3.2-± 1.1-fold (n = 3); and for rat astrocyte mGluR5, 10 µM quisqualate versus buffer was 2.3-± 0.2-fold (n = 6). Signal-to-noise ratios were comparable to literature values described for these receptors. [15] [16] [17] [18] 22 Antagonists known to block the M1 receptor and mGluR5 activation effectively blocked agonist-induced IP accumulation ( Fig. 2A,C) .
Small-molecule selective antagonists of hGalR 2 have yet to be described in the literature.
Validation of the 96-well-formatted mini-column assay for measurement of M1-mediated IP accumulation in CHO cells
Several key assay parameters were optimized in the CHO-M1 cells to maximize the signal-to-noise ratio. The first parameter evaluated was cell density (Fig. 3A) . Because cells were prelabeled with [ 3 H]myo-inositol in T150 flasks and then detached, counted, reconstituted to the desired dilution, and assayed in suspension, the density of cells achievable per well was substantially greater than if the cells had been seeded directly onto the 96well plate and assayed while attached. It was determined that 300,000 to 500,000 cells per well reliably produced signal-tonoise ratios and cpm similar to the large-volume, gravity-fed column reference assay, with a block by an appropriate antagonist, nitrocaramiphen (Fig. 3A) .
A second parameter evaluated was the volume of the anionexchange resin slurry added to each mini-column (Fig. 3B ). The resin mixture was added rapidly and precisely using a standard digital pipettor (1200 µL BioHit) to minimize slurry settling. This is important as it prevents an uneven amount of resin deposited across the columns. This problem frequently occurs in the largecolumn assay due to the lack of rapid or precise tools for adding large resin volumes to the columns. It was determined that 300 to 450 µL of resin per mini-column reliably yielded signal-to-noise ratios and cpm comparable to the large-volume, gravity-fed column reference assay, with a block by an appropriate antagonist, telenzepine (Fig. 3B) .
A third parameter that was evaluated was the duration of agonist stimulation (Fig. 3C ). This timing was achieved very precisely by rapid 12-channel (100 µL BioHit) serial dispensing of 5 µL PCA to stop the reaction. The data demonstrate that the 20-min agonist incubation reliably yielded signal-to-noise ratios and cpm comparable to the large-volume, gravity-fed column reference assay, with a block by an appropriate antagonist, telenzepine (Fig.  3C ).
Optimized assay conditions in CHO-M1 cells (yielding average signal-to-noise values of 6.3 ± 1, n = 5) were used to test agonist concentration dependence on IP accumulation. The M1 agonists tested were acetylcholine and carbachol (Fig. 4A) . Agonist-induced IP accumulation was concentration dependent, with EC 50 values of 17.5 ± 3.7 nM (n = 4) for acetylcholine and 1.7 ± 0.9 µM (n = 3) for carbachol, consistent with literature values. 27 In a concentration-dependent manner, telenzepine and nitrocaramiphen inhibited 100 µM carbachol-induced IP accumulation, with complete inhibition at saturating concentrations (Fig. 4B) . The average IC 50 values determined were 204 ± 45 nM (n = 3) for telenzepine and 1.3 ± 0.7 µM (n = 3) for nitrocaramiphen. Conversion of the average IC 50 value for each antagonist using the Cheng-Prusoff equation, as described in Materials and Methods, yielded a K b value of 3.2 nM for telenzepine and 21 nM for nitrocaramiphen, consistent within approximately 3-to 4-fold of literature K i values determined using radioligand binding assays (1 nM telenzepine, 5.5 nM nitrocaramiphen 28 ).
Validation of the 96-well-formatted mini-column assay for measurement of hGalR 2 -mediated IP accumulation in HEK-293 cells
The same assay parameters that were optimized for CHO-M1 cells were applied to measure hGalR 2 -mediated IP responses in stably transfected HEK cells (Fig. 5A ). Under these conditions, signal-to-noise values (3.4 ± 0.7, n = 3) were comparable to the large-volume, gravity-fed column reference assay. The concentration dependence of IP accumulation for the hGalR 2 peptides hGalanin and M35 were also evaluated ( Fig. 5B ). Both peptides induced, in a concentration-dependent manner, IP accumulation with similar EC 50 values (hGalanin, 89 ± 14.5 nM, n = 3; M35, 119 ± 42 nM, n = 3). The hGalanin EC 50 value is approximately 20-fold lower in potency than previously reported for hGalanin-stimulated IP accumulation using a similar cell line. 29 However, calcium measurement responses to hGalanin in our cell line also showed 20-to 40-fold less potency (40 ± 20 nM, n = 4) versus this same report (0.7 nM), indicating there may be differences in B max values or G protein-coupling efficiencies. Due to the current lack of docu-mented small-molecule selective antagonists for hGalR 2 , we were not able to provide further validation for this receptor.
Validation of the 96-well-formatted mini-column assay for measurement of native mGluR5-mediated IP accumulation in rat primary astrocytes
A typical shortfall of many miniaturized or HTS-adapted assays is sufficient sensitivity to achieve reliable measurements in native cells or tissues, in contrast to recombinant cell systems in which the biological target is overexpressed and the cell line is selected for robust functional responses. Rat primary astrocytes are reported to express selectively mGluR5 type I metabotropic glutamate receptors but not mGluR1, 22 the only 2 metabotropic glutamate receptors known to couple to Gq in mammalian cells. 30, 31 Therefore, we evaluated whether the mini-column assay could be adapted for measuring endogenously expressed mGluR5mediated IP accumulation in these primary cells. Cell density, optimized to 800,000 cells/well (data not shown), achieved a 2.1-± 0.2-fold (n = 9) signal-to-noise ratio in these cells, comparable to that achieved with the large-volume, gravity-fed column reference assay. Application of the nonselective metabotropic glutamate receptor agonists, glutamate and quisqualate, stimulated significant IP accumulation responses in these cells that were blocked by the selective mGluR5 antagonist MPEP (Fig. 6A ). Agonist-induced IP accumulation was concentration dependent, with EC 50 values of 237 ± 59 nM for quisqualate and 12.2 ± 6.7 µM for glutamate ( Fig.  6B) , consistent with literature values. 32 
DISCUSSION
The rapid and accurate assessment of GPCR-mediated PLC pathway activation, particularly IP accumulation, is valuable for a number of pharmaceutical discovery and basic research needs. First, an IP accumulation assay is useful for elucidating compound target site action. For example, an IP 3 assay can confirm results generated in a GPCR calcium mobilization screen. This would ensure that "hits" from an HTS are not nonspecifically affecting cellular calcium physiology but indeed are interacting with the GPCR target. Second, an IP accumulation assay is useful for investigating GPCR constitutive activity [33] [34] [35] because IP 3 and its downstream phosphoinositol metabolites can be trapped in the presence of the inositol monophosphatase inhibitor lithium. 14 Constitutive activity is particularly difficult to monitor using common calcium mobilization assays, as calcium extrusion pumps and intracellular calcium uptake mechanisms rapidly and efficiently achieve tight regulation of cytosolic calcium levels. Last, an IP accumulation assay can be used to investigate a compound's mechanism of interaction with the target. For example, distinguishing whether a compound is an agonist, a competitive or noncompetitive antagonist, or an inverse agonist is possible. It is particularly useful for distinguishing whether a compound is an inverse agonist or an antagonist because of its suitability for investigating GPCR constitutive activity. 33, 34 Thus, the present study describes a feasible, miniaturized, and simplified approach to measuring receptor-mediated IP accumulation from living cells. The general assay concept is similar to classical methods in that [ 3 H]myo-inositol prelabeling of cells, coupled with anion-exchange chromatographic analysis of IP accumulation, is a key step to this assay method. However, the miniaturized approach incorporates several key changes, includ-ing stimulation of cells in suspension, use of 96-well-formatted mini-columns, and solid scintillator-coated microplates. These changes confer several important advantages, including accurate control of cell number, minimization of resin and sample volumes for ease of use with common digital pipettors or screening laboratory robotics, elimination of liquid scintillation cocktails, and minimization of background luminescence. This improved method reliably measures receptor-mediated IP accumulation with signal-to-noise ratios and reproducibility comparable to the classical large-volume, column-based methods. Moreover, the miniaturized format saves time and reagents, is conducted in a standard 96-well compound screening format, and is compatible with common HTS laboratory equipment. In addition, the assay is applicable to IP accumulation measurements from recombinant cell systems and primary cells.
Two GPCR-mediated IP 3 assays are available commercially for compound screening or pharmacological profiling. These assays are the PerkinElmer (Boston, MA) [ 3 H]Radioreceptor Assay Kit, and the PerkinElmer (Boston, MA) AlphaScreen™ IP 3 Assay Kit. Both have advantages over classical large-column IP accumulation assays, but they also have several limitations. The [ 3 H]radioreceptor assay benefits from its quantitative, specific measurement of IP 3 and a relatively low (< 1 mL) assay volume. However, a significant drawback is that this assay requires many technical manipulations. Similar to the large-volume, gravity-fed columns assay, an acid extraction using trioctylamine/ trichlorotrifluoroethane in microcentrifuge tubes is necessary. Multiple-tube centrifugation, as well as laborious transfer and vortexing steps, is also required and can lead to variability. IP 3 production is measured using large scintillation vials and ≥ 5-mL scintillation cocktail per sample. Furthermore, the assay is specific for IP 3 and cannot detect downstream IPs, so its performance depends on rapid capture of cellular IP 3 within seconds of agonist stimulation and does not take advantage of signal amplification by measuring lithium-mediated accumulation of downstream molecules. 14 In contrast, the AlphaScreen™ IP 3 assay is a homogeneous, nonradioactive assay amenable to both 96-and 384-well formats. No centrifugation, transfer, or chromatographic steps are required. Cells are stimulated in suspension, allowing precise cell number determinations. Importantly, an AlphaQuest®-HTS or a Fusion™ αMicroplate Analyzer (both available through PerkinElmer, Boston, MA) is a required plate reader for the AlphaScreen™ chemistry. Both instruments are available in most screening laboratories. An unusual precaution necessary to run a successful AlphaScreen™ assay is subdued lighting, or preferably greenwavelength light, as a key assay reagent is highly light sensitive. One of the major limitations of the AlphaScreen™ assay is signal sensitivity to the cell number. For example, as little as 2000 CHO cells/well quench the signal by 10-fold. 10 Thus, measurements in cells other than robustly engineered recombinant cell lines, such as primary cells, can be problematic. Also, as the AlphaScreen™ assay specifically measures IP 3 plification does not occur. 14 Therefore, only GPCRs that do not desensitize significantly within the required 10-sec agonist stimulation step, a duration that approaches the limits of pipettingspeed capability, are optimal for this assay format. For example, as mGluR5 rapidly desensitizes, 36 it may prove difficult to assay using the AlphaScreen™ approach. So far, no validation of mGluR5 using AlphaScreen™ has been reported. The mini-column-based IP accumulation assay described here has several advantages over other current techniques. The main advantage is that the assay can be performed more quickly and simply than classical anion-exchange chromatographic procedures, yet it still takes advantage of signal amplification that occurs when measuring both IP 3 and downstream IPs. 14 Thus, this assay is amenable to a greater diversity of cell types, including recombinant or primary cells, and a wider variety of GPCR targets, including rapidly desensitizing receptors. However, the major limitation of the assay is that it is a nonhomogeneous format. Plate centrifugation and transfer steps are required. The centrifugation steps could be transitioned to a vacuum manifold for the chromatographic elutions, opening the possibility of automation. Indeed, some preliminary testing in our laboratory suggests that vacuum-based sample elution works well for CHO-M1s (data not shown). As this assay is not specific for IP 3 , it will not be useful if specific measurement of IP 3 is necessary, such as in the investigation of GPCR desensitization kinetics. In that case, the AlphaScreen™ IP 3 assay, the [ 3 H]radioreceptor assay, or perhaps some of the highly sensitive HPLC-and GC/MS-based methods may be more applicable. [5] [6] [7] Finally, although the assay is useful for cell types with lower levels of receptor expression, such as for mGluR5 in rat primary astrocytes, it requires significantly more optimization to achieve acceptable signal-to-noise ratios when cellular receptor densities are relatively low. In such cases, high cell densities may be required to measure a reliable signal, thereby precluding HTS using this assay. Thus, the mini-column IP accumulation assay is highly dependent on GPCR expression levels and is typically more robust when a highly expressing engineered cell line is available. Overall, however, the assay represents a viable alternative to existing IP 3 assays, especially when GPCR expression is not extremely robust or GPCR desensitization kinetics are rapid.
